索提林抑制治疗多种神经退行性溶酶体储存障碍
Hannah G Leppert1, Joelle T Anderson1, Kaylie J Timm1
1Pediatrics and Rare Diseases Group, Sanford Research, Sioux Falls, SD.
bioRxiv : the preprint server for biology
|October 4, 2023
概括
一种新的小分子抑制剂索尔提林,AF38469,显示出治疗巴顿病的前景. 这种疗法改善了 lysosomal 功能,并减少了小鼠模型中的神经炎症,为这些严重的 lysosomal 存储障碍提供了新的治疗途径.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 生物化学 生物化学
背景情况:
- lysosomal储存障碍 (LSDs) 是一组多样化的遗传疾病,导致 lysosomal 功能障碍.
- 巴顿病是一种严重的LSD,主要影响中枢神经系统,导致衰弱的神经症状.
结论:
- 索尔提林抑制是一种新且有效的治疗策略,用于各种形式的巴顿病.
- AF38469在改善巴顿病的关键病理特征方面显示出显著的潜力.
更多相关视频
相关概念视频
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
siRNA - Small Interfering RNAs
16.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.8K
Parkinson's Disease: Treatment
292
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
292
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212


